Stock GPCR STRUCTURE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Structure Therapeutics Inc.

Equities

GPCR

US86366E1064

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
36.15 USD +0.75% Intraday chart for Structure Therapeutics Inc. +0.92% -11.31%
05-09 Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-09 Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
GL
Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target
MT
ADRs Edge Higher; Lufax Climbs Almost 46%
DJ
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
AQ
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
GL
Structure Therapeutics Q4 Loss Widens
MT
Structure Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Structure Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
GL
Health Care Down on Growth Bias -- Health Care Roundup
DJ
ADRs Advance, Fanhua Inc. Climbs 26.7%
DJ
Structure Therapeutics Shares Tumble After Update on GSBR-1290 for Weight Loss
MT
Structure's diabetes pill misses weight-loss expectations in mid-stage trial
RE
Structure Therapeutics Inc. Provides Comprehensive GSBR-1290 Program Update
CI
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
AQ
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
GL
Structure Therapeutics Inc.(NasdaqGM:GPCR) added to NASDAQ Biotechnology Index
CI
ADRs Slump; FLJ Group Ltd. Declines 13.7%
DJ
JMP Securities Adjusts Structure Therapeutics' Price Target to $91 From $90, Keeps Market Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GPCR Stock
  4. News Structure Therapeutics Inc.